medicine forum beginner
Joined: 09 Jun 2005
|Posted: Thu Mar 30, 2006 5:21 pm Post subject:
Nanobac Pharmaceuticals March 30th Press Release
Nanobac Pharmaceuticals, Inc. Launches International Team to Test
Promising New Therapy for Stone Forming Diseases
TAMPA, Fla., Mar 30, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals,
("Nanobac" or "the Company") announced today new initiatives focusing
on diagnostic and therapeutic solutions for stone forming diseases.
Capitalizing on its intellectual property estate, recent discoveries
and pending intellectual property, the Company will utilize a team of
internationally recognized medical and drug development experts to test
a promising drug combination and diagnostics that might improve patient
outcomes in painful stone-forming diseases such as prostatitis,
gallstones and kidney stones where no effective treatment is available.
The Company has worked with researchers from Cleveland Clinic and Mayo
Clinic, has ongoing research at NASA and the University of California
San Francisco, and is adding research teams from Sweden and Finland to
test the discovery of a drug combination found to inhibit calcifying
nanoparticles associated with stone forming diseases. Work on
diagnostic solutions has already begun or been concluded in some
In support of its new initiatives, Nanobac announced today that Dr.
Benedict S. Maniscalco, a cardiologist with extensive experience
treating calcification-related conditions, has been appointed head of
research initiatives and Co-Chairman of the Board.
Dr. Maniscalco has been repeatedly voted by physician peers as one of
the "Best Doctors in America." He founded St. Joseph's Hospital Heart
Institute in Tampa and is head of the internationally recognized
Heartbeat International which donates life saving pacemakers in lesser
developed countries. He was principle investigator in a study on a
novel therapy for atherosclerosis.
Dr. Hector Gomez, M.D. PhD, will be special advisor to Dr. Maniscalco
on drug and diagnostics development. He is a former Merck and Novartis
research executive with extensive experience bringing therapies to
market in FDA and European regulatory environments, and in supervising
clinical trial work in other countries. He has successfully brought
biotech companies public and currently heads an R&D company near Tampa.
"Dr. Maniscalco's and Dr. Gomez' combination of clinical treatment,
medical innovation and drug development experience adds a needed
dimension to the quest for an effective treatment for stone forming
diseases," said John Stanton, CEO and Chairman. "This will enhance our
focus on proving the effectiveness of drug combinations in ways that
will meet new FDA drug and diagnostics standards."
"This initiative has the added advantage of being tied to diagnostics
to measure patient improvements before other methods can," Dr.
Maniscalco said. "That capability comes from measuring the level of
calcifying nanoparticles in blood."
The same calcified particles found in stone-forming diseases are found
in atherosclerosis, but until now have been hard to diagnose or treat.
Dr. Maniscalco has extensive experience treating coronary
The Company also announced that, effective immediately, Nanobac is
narrowing its near-term focus to improving patient outcomes with drug
combinations for such diseases, and will discontinue the sale of
supplements and nutraceuticals.
The initiative follows the filing of multiple patent applications with
regard to stone forming diagnostics and therapies and the publishing of
an observational study at Cleveland Clinic showing that prostatitis
patients improve with our experimental drug combination, and that no
serious adverse reactions were encountered. Another combination therapy
patented by Nanobac has shown promising results in vitro. The team will
focus on that new combination.
"This is an exciting new start for patients with stone forming
diseases, and for Nanobac," Dr. Maniscalco concluded, "The focus is
extremely sharp. We are attacking stone forming diseases with a
potentially effective and uniquely measurable drug combination whose
effects could be shown in the early phase using new diagnostics."
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a broad-based life science company
dedicated to the discovery and developments of products and services to
improve people's health through the detection and treatment of
Calcifying Nano-Particles, otherwise known as "nanobacteria". The
Company's pioneering research is establishing the pathogenic role of
nanobacteria in soft tissue calcification, particularly in coronary
artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
reagents for the detection of Calcifying Nano-Particles. IVD products
include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
Nano-Vision(TM) line of antibodies and reagents. Nanobac's
BioAnalytical Services works with biopharmaceutical partners to develop
and apply methods for avoiding, detecting, and inactivating or
eliminating CNPs from raw materials. Nanobac's Drug Discovery and
Development efforts are focused on developing new and existing
compounds that effectively inhibit, destroy or neutralize CNPs.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For
more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this
document as well as some statements in periodic press releases and some
oral statements of Nanobac Pharmaceuticals, Inc. officials are
"Forward-Looking Statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
statements include statements which are predictive in nature, which
depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects,"
and similar expressions. In addition, any statements concerning future
financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future
Nanobac Pharmaceuticals, Inc. actions, which may be provided by
management, are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by
such forward-looking statements and to vary significantly from
reporting period to reporting period. Although management believes that
the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance
and Nanobac Pharmaceuticals, Inc. has no specific intention to update
SOURCE: Nanobac Pharmaceuticals, Inc.
Nanobac Pharmaceuticals, Inc., Tampa, Contact: Karen Taylor,
Copyright Business Wire 2006
The time now is Tue Oct 16, 2018 7:22 am | All times are GMT
Copyright © 2004-2005 DeniX Solutions SRL
Other DeniX Solutions sites:
email marketing campaigns ,
Powered by phpBB © 2001, 2005 phpBB Group